MIDOSTAURIN
| Brand name | RYDAPT |
|---|---|
| Active ingredient | MIDOSTAURIN |
| Strength | 25MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8575146 | December 2030 | use U-2008 |
| 7973031 | October 2028 | use U-2007 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.